Lars Lundin

Specialistläkare vid Institutionen för kirurgiska vetenskaper; Molekylär avbildning och medicinsk fysik

E-post:: lars.lundin@uu.se
Besöksadress:: Akademiska sjukhuset, ingång 70, 1tr
Postadress:: Akademiska sjukhuset, ingång 70, 1tr
751 85 UPPSALA

Ladda ned kontaktuppgifter för Lars Lundin vid Institutionen för kirurgiska vetenskaper; Molekylär avbildning och medicinsk fysik

Akademiska meriter:: Specialistläkare, MD

Publikationer

Senaste publikationer

Homozygosity for a missense variant in COMP gene associated with severe pseudoachondroplasia

Tariq, M.; Khan, T. N.; Lundin, Lars; Jameel, M. et al.

Ingår i Clinical Genetics, s. 182-186, 2018
- DOI för Homozygosity for a missense variant in COMP gene associated with severe pseudoachondroplasia
Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity

Garske, Ulrike; Sandström, Mattias; Fröss-Baron, Katarzyna; Lundin, Lars et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, s. 970-988, 2018
- DOI för Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity
- Ladda ner fulltext (pdf) av Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity

Alla publikationer

Artiklar i tidskrift

Homozygosity for a missense variant in COMP gene associated with severe pseudoachondroplasia

Tariq, M.; Khan, T. N.; Lundin, Lars; Jameel, M. et al.

Ingår i Clinical Genetics, s. 182-186, 2018
- DOI för Homozygosity for a missense variant in COMP gene associated with severe pseudoachondroplasia
Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity

Garske, Ulrike; Sandström, Mattias; Fröss-Baron, Katarzyna; Lundin, Lars et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, s. 970-988, 2018
- DOI för Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity
- Ladda ner fulltext (pdf) av Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity